Clinical trials: Overweight or Obesity
Overweight and Obesity, Cardiovascular Risk Factors
Web-based Personal or Peer Group Weight Management Study
The PERGROUP trial aims to investigate whether Web-based personal or Web-based group counselling weight management program can help to achieve lifestyle changes needed for weight loss and improvement in quality of life and…
- Conditions
- Overweight and Obesity, Cardiovascular Risk Factors, Quality of Life, Work Ability
- Trial name
- PERGROUP (NCT03904160)
- Testing
- Weight management
- Where
- Finland
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University of Turku
Obese or Overweight Healthy Volunteers
Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
- Trial name
- NCT07098624
- Testing
- ACV Moringa Effervescent Tablets 4.3 g
- Volunteers
- 66 people
- Sponsor
- NovoBliss Research Pvt Ltd
Insulin Sensitivity, Overweight or Obesity
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
Objective 1: Characterize indices of systemic inflammation and gut microbiota composition and function after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants.
- Conditions
- Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
- Trial name
- PS (NCT04267705)
- Testing
- Control, Black bean, Chickpea
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity, Childhood, Pediatric Obesity
Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers
The US Preventive Services Task Force (USPSTF) recommends that providers screen children aged 6 years and older for obesity and offer or refer them to a comprehensive behavioral intervention (≥26 hours over a period of up to 12…
- Conditions
- Obesity, Childhood, Pediatric Obesity, Childhood Obesity, Adolescent Obesity
- Trial name
- TEAM UP (NCT03843424)
- Testing
- eSOC program, FBT program
- Where
- 7 sites in United States
- Volunteers
- 1,460 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Overweight and Obesity
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in…
- Trial name
- NCT07717814
- Testing
- AMG 133 (frozen liquid), AMG 133 (liquid)
- Where
- 4 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Amgen
Obesity
Anti-psychotic Medication (New Use) Weight Loss Study
This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain…
- Trial name
- NCT01272752
- Testing
- IHBG-10
- Where
- United States
- Sponsor
- Avera McKennan Hospital & University Health Center
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female…
- Trial name
- NCT00747929
- Testing
- S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
- Where
- 38 sites in United States
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity, Overweight
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- KaiNETIC-1 (NCT07284875)
- Testing
- Ribupatide
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 2,530 people
- Sponsor
- Kailera
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight.
- Trial name
- NCT06207877
- Testing
- Cagrilintide, Semaglutide
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese
A Study to Evaluate MWN109 Injection in Healthy Subjects
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
- Trial name
- NCT06859853
- Testing
- Subcutaneous single and mutiple dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Obesity/Overweight in Adult
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate…
- Trial name
- NCT07150975
- Testing
- GZR18, Semaglutide(Wegovy® )
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance.
- Trial name
- NCT07555730
- Testing
- AI assisted multi-domain lifestyle intervention, Tirzepatide
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Huazhong University of Science and Technology
Overweight or Obesity
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic…
- Trial name
- NCT07150962
- Testing
- HRS-9531 Tablet
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Obesity
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
- Trial name
- NCT00533481
- Testing
- MK0557
- Volunteers
- 497 people
- Sponsor
- Merck Sharp & Dohme LLC